Top 100 Outlook 2021: Medtechs Look To Build On Experiences Of Serving Global Markets In A Pandemic

If necessity is the mother of invention, then medtech firms know what is expected of them in 2021 ̶ how they achieve it might be less straightforward

Medtechs took a long look at themselves as they rose to the challenges of COVID-19. How they responded, repurposed and regrouped to tackle the coronavirus was both sobering and uplifting. The lessons of 2020 must be integrated into the digitally-enabled health care systems of 2021 and beyond.

Outlook for 2021 - Message written on a poster.

COVID-19 has compelled medtech manufacturers, and regulators and governments too, to take a good look at what they do, and assess how they can do it better. Many have also been openly asking why haven’t they done it better. There is nothing like a crisis to focus the mind.

More open regulatory pathways have given medtechs the scope to innovate more rapidly. There are examples aplenty of turbocharged product development for COVID-19 technologies, including ventilators and innovative tests.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

FDA Halts Acceptance Of Chinese Lab Data Due To Accuracy Issues

 
• By 

The FDA has stopped accepting data from two Chinese labs due to accuracy issues. Mid-Link and SDWH have been flagged for potentially falsified results and other misconduct. This decision, which follows months of discussions and warnings, emphasizes the FDA's commitment to ensuring data integrity in medical device submissions.

TRiCares Tricuspid Valve Replacement System Reduces Regurgitation In First-In-Human Study

 

TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.

Guardant Health Launches Germline Hereditary Cancer Test

 

Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.

Edwards Lifesciences Holds 2025 EPS Outlook Despite Tariff Headwind

 
• By 

The brunt of the tariff exposure stems from Singapore and Costa Rica, which together account for an estimated 70% to 80% of the tariff-related cost burden. Less than 10% of the exposure is tied to China.

More from Medtech Insight

Swiss Medtechs Advised To Work On US Tariff Mitigation Strategies

 
• By 

The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.

Guardant Health Launches Germline Hereditary Cancer Test

 

Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.

FDLI: Clinical Labs Face Uncertainty After Texas Court’s LDT Ruling

 
• By 

A Texas court's decision against US FDA regulation of lab-developed tests (LDTs) has introduced new uncertainties for clinical labs. Industry stakeholders are now worried about potential future regulations while also managing existing compliance requirements. Recent conference discussions underscored the complexities of FDA oversight.